A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jan 29, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how different doses of tranexamic acid (TXA) can help reduce blood loss during hip replacement surgery, also known as total hip arthroplasty. TXA is a medication that can help prevent excessive bleeding, and the researchers want to find the best dose to use. The trial is currently recruiting participants who are planning to have this surgery.

To be eligible for this study, you should be between 65 and 74 years old and need a hip replacement for a condition that has lasted less than three months. It's important that you are part of the French Social Security Healthcare system and can give your consent or have a representative do so for you. However, if you've had a hip fracture in the last three months, have certain health issues, or are pregnant, you may not be able to participate. If you join the trial, you can expect to receive either the study medication or a placebo (a treatment with no active ingredients) before your surgery, and your progress will be monitored closely. This study aims to improve patient care by finding the most effective dose of TXA for hip surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient requiring primary hip arthroplasty (less than 3 months)
• • Informed Consent from the patient or their legally authorized representative
• • Affiliation to French Social Security Healthcare system
• Exclusion Criteria:
• • Hip fracture of less than 3 months
• • Bilateral hip arthroplasty or anterior approach to hip arthroplasty
• • Haemorrhagic surgery in the previous 2 weeks
• • Contraindication to tranexamic acid
• • Contraindication to apixaban
• • Chronic use of anticoagulant
• • Pregnancy
• • Previous participation to this study